JP2018532748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532748A5 JP2018532748A5 JP2018521987A JP2018521987A JP2018532748A5 JP 2018532748 A5 JP2018532748 A5 JP 2018532748A5 JP 2018521987 A JP2018521987 A JP 2018521987A JP 2018521987 A JP2018521987 A JP 2018521987A JP 2018532748 A5 JP2018532748 A5 JP 2018532748A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- composition
- cathepsin
- amyloidosis
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248713P | 2015-10-30 | 2015-10-30 | |
| US62/248,713 | 2015-10-30 | ||
| PCT/US2016/059587 WO2017075540A1 (en) | 2015-10-30 | 2016-10-28 | Methods and compositions for the treatment of amyloidosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018532748A JP2018532748A (ja) | 2018-11-08 |
| JP2018532748A5 true JP2018532748A5 (enExample) | 2019-12-05 |
Family
ID=58631207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521987A Pending JP2018532748A (ja) | 2015-10-30 | 2016-10-28 | アミロイドーシス治療のための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20170119861A1 (enExample) |
| EP (1) | EP3368048A4 (enExample) |
| JP (1) | JP2018532748A (enExample) |
| CN (1) | CN108367018A (enExample) |
| AR (1) | AR106538A1 (enExample) |
| AU (1) | AU2016343812A1 (enExample) |
| BR (1) | BR112018008839A8 (enExample) |
| CA (1) | CA3002410A1 (enExample) |
| MX (1) | MX2018005352A (enExample) |
| TW (1) | TW201729833A (enExample) |
| WO (1) | WO2017075540A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4714496A3 (en) * | 2018-05-01 | 2026-04-29 | OrfoNeuro ApS | Treatment of neuronal ceroid lipofuscinosis |
| PL4094754T3 (pl) | 2018-06-19 | 2026-01-05 | Universidad Pablo De Olavide | Kompozycje do leczenia chorób związanych z agregacją białek i/lub zapobiegania takim chorobom |
| KR20210131991A (ko) | 2018-11-14 | 2021-11-03 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 구획-특이적 카고 전달을 위한 조성물 및 방법 |
| CN109701040B (zh) * | 2019-03-08 | 2021-04-06 | 昆明医科大学第一附属医院 | 一种用于诊治mtc的纳米pamam靶向多肽放射性核素制剂及制备方法 |
| WO2020214033A1 (en) * | 2019-04-17 | 2020-10-22 | Erasmus University Medical Center Rotterdam | Papain-like cysteine peptidase medicaments and uses thereof |
| CN114555800A (zh) * | 2019-07-05 | 2022-05-27 | 国立大学法人德岛大学 | 经修饰的神经氨酸酶 |
| US20260092290A1 (en) * | 2022-12-21 | 2026-04-02 | National Taiwan University | Recombinant viral vector, recombinant adeno-associated virus comprising the same, and uses thereof in treating sialidosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000050886A (ja) * | 1998-06-05 | 2000-02-22 | Fuji Chemical Industries Ltd | 新規なヒトカテプシンｌ２タンパク質及びそれをコ―ドする遺伝子並びにそれらの利用 |
| CA2446127A1 (en) * | 2001-05-16 | 2002-11-21 | Biomarin Pharmaceutical Inc. | Destruction of prions using vibriolysin or variants thereof |
| US8137666B2 (en) * | 2008-11-22 | 2012-03-20 | Academia Sinica | Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses |
| US9138465B2 (en) * | 2011-04-28 | 2015-09-22 | Osaka University | Pharmaceutical composition for treating lysosomal storage disease |
| DK2751279T3 (da) * | 2011-08-31 | 2017-11-20 | St Jude Children's Res Hospital | Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse |
| WO2013176694A1 (en) * | 2012-05-22 | 2013-11-28 | Berg Pharma Llc | Interrogatory cell-based assays for indentifying drug-induced toxicity markers |
| JP2014144933A (ja) * | 2013-01-29 | 2014-08-14 | Kwangju Inst Of Science & Technol | アミロイドβの除去 |
-
2016
- 2016-10-28 AU AU2016343812A patent/AU2016343812A1/en not_active Abandoned
- 2016-10-28 JP JP2018521987A patent/JP2018532748A/ja active Pending
- 2016-10-28 CN CN201680072193.9A patent/CN108367018A/zh active Pending
- 2016-10-28 US US15/338,242 patent/US20170119861A1/en not_active Abandoned
- 2016-10-28 BR BR112018008839A patent/BR112018008839A8/pt active Search and Examination
- 2016-10-28 WO PCT/US2016/059587 patent/WO2017075540A1/en not_active Ceased
- 2016-10-28 CA CA3002410A patent/CA3002410A1/en active Pending
- 2016-10-28 EP EP16861010.3A patent/EP3368048A4/en not_active Withdrawn
- 2016-10-28 MX MX2018005352A patent/MX2018005352A/es unknown
- 2016-10-31 AR ARP160103322A patent/AR106538A1/es not_active Application Discontinuation
- 2016-10-31 TW TW105135250A patent/TW201729833A/zh unknown
-
2018
- 2018-12-19 US US16/226,092 patent/US20190183985A1/en not_active Abandoned
-
2020
- 2020-10-08 US US17/065,836 patent/US20210228694A1/en not_active Abandoned
-
2022
- 2022-09-06 US US17/930,014 patent/US20230127775A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tammaro et al. | Metabolic flexibility and innate immunity in renal ischemia reperfusion injury: the fine balance between adaptive repair and tissue degeneration | |
| Petrovic-Djergovic et al. | Inflammatory disequilibrium in stroke | |
| ZA202202410B (en) | Rna particles comprising polysarcosine | |
| EP2670434A2 (en) | Treatment of tauopathies | |
| SI2999785T1 (en) | SERPINA1 IRNA assemblies and procedures for their use | |
| CN107405380A (zh) | 用于预防听觉损伤的肽及其包含该肽的组合物 | |
| WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
| NZ597489A (en) | Methods for treating conditions associated with MASP-2 dependent complement activation | |
| JP2011103891A5 (enExample) | ||
| MX2012004343A (es) | Metodos para el tratamiento de la coagulacion intravascular diseminada mediante la inhibicion de la activacion del complemento dependiente de la masp-2. | |
| JP2016516073A5 (enExample) | ||
| EP2808029A3 (en) | Combination therapies using cyclosporine and aromatic cationic peptides | |
| RU2016113055A (ru) | Композиция для лечения и профилактики доброкачественной гиперплазии простаты | |
| HRP20171909T1 (hr) | Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe | |
| Pinsky | Inflammatory Disequilibrium in Stroke | |
| JP2018516944A5 (enExample) | ||
| Ishrat et al. | Vascular protection to increase the safety of tissue plasminogen activator for stroke | |
| AR106538A1 (es) | Métodos y composiciones para el tratamiento de la amiloidosis | |
| WO2018155813A3 (ko) | 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2 | |
| CA2646589C (en) | Inhibition of tumour growth | |
| UA112752C2 (uk) | Лікарський засіб та метод блокування утворення або посилення знищення білка p24 | |
| WO2020055906A8 (en) | Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k) | |
| JP6169607B2 (ja) | 抗腫瘍アジュバント療法 | |
| CA2549185A1 (en) | Peptide inhibiting angiotensin converting enzyme | |
| JP2015061874A (ja) | カルパイン阻害のための方法、系および組成物 |